Abstract
Long-term outcome was analyzed in 28 patients transplanted between 1989 and 1992 following busulfan and cyclophosphamide and who had busulfan levels studied. While there was no significant correlation of busulfan levels with diagnosis, patients who had received extensive prior chemotherapy had a significantly higher area under the curve (AUC; P = 0.02) and maximum busulfan levels (Cmax; P = 0.03). High AUC was associated with the development of hepatic veno-occlusive disease (P = 0.03) and with early transplant-related mortality (P = 0.06). No significant correlation of busulfan levels with relapse, late non-relapse death, late complications, nor event-free survival was detected. Bone Marrow Transplantation (2001) 27, 1121–1124.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide New Engl J Med 1983 309: 1347–1353
Tutschka PJ, Copelan EA, Klein JP . Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen Blood 1987 70: 1382–1388
Vaughan WP, Dennison JD, Reed EC et al. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy Bone Marrow Transplant 1991 8: 489–495
Avalos BR, Klein JL, Kapoor N et al. Preparation for marrow transplantation in Hodgkin's and non-Hodgkin's lymphoma using Bu/Cy Bone Marrow Transplant 1993 12: 133–138
Dimopoulos MA, Alexanian R, Przepiorka D et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myleoma Blood 1993 82: 2324–2328
Grochow LB, Jones RJ, Brundett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation Cancer Chemother Pharmacol 1989 25: 55–61
Ljungman P, Hassan M, Bekassy AN et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients Bone Marrow Transplant 1997 20: 909–913
Slattery JT, Sanders JE, Buckner CD et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 1995 16: 31–42
Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation Blood 1997 89: 3055–3060
MacKichan JJ, Bechtel TP . Quantitation of busulfan in plasma by high performance liquid chromatography J Chromatogr 1990 532: 424–428.
McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 1993 11: 255–267
Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 1988 6: 1562–1568
Shulman HM, Sale GE, Lerner KG et al. Chronic cutaneous graft-versus-host disease in man Am J Pathol 1978 91: 545–570
Clark JG, Crawford SW, Madtes DK, Sullivan KM . Obstructive lung disease after allogeneic marrow transplantation Ann Intern Med 1989 111: 368–376
Mann HB, Whitney DR . On a test of whether one of 2 random variables is stochastically larger than the other Ann Math Statist 1947 18: 50–60
Kruskal WH, Wallis WA . Use of ranks in one criterion variance analysis J Am Stat Assoc 1952 47: 583–621
Gibbs JP, Gooley T, Corneau B et al. The impact of obesity and disease on busulfan oral clearance in adults Blood 1999 93: 1–5
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Copelan, E., Bechtel, T., Avalos, B. et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 27, 1121–1124 (2001). https://doi.org/10.1038/sj.bmt.1703047
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703047
Keywords
This article is cited by
-
Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation (2022)
-
Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
Annals of Hematology (2021)
-
Busulfan systemic exposure and its relationship with efficacy and safety in hematopoietic stem cell transplantation in children: a meta-analysis
BMC Pediatrics (2020)
-
Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation
Cancer Chemotherapy and Pharmacology (2020)
-
Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children
Bone Marrow Transplantation (2019)